NATCO Pharma Dirección
Dirección controles de criterios 1/4
El CEO de NATCO Pharma es Rajeev Nannapaneni, nombrado en Jun 2012, tiene una permanencia de 12.42 años. posee directamente un 0.63% de las acciones de la empresa, con un valor de ₹1.61B. La antigüedad media del equipo directivo y de la junta directiva es de 7.8 años y 2.3 años, respectivamente.
Información clave
Rajeev Nannapaneni
Chief Executive Officer (CEO)
₹98.7m
Compensación total
| Porcentaje del salario del CEO | n/a |
| Permanencia del CEO | 12.4yrs |
| Participación del CEO | 0.6% |
| Permanencia media de la dirección | 7.8yrs |
| Promedio de permanencia en la Junta Directiva | 2.3yrs |
Actualizaciones recientes de la dirección
Recent updates
We Ran A Stock Scan For Earnings Growth And NATCO Pharma (NSE:NATCOPHARM) Passed With Ease
Oct 13
NATCO Pharma Limited's (NSE:NATCOPHARM) Shares Bounce 26% But Its Business Still Trails The Market
Aug 13If EPS Growth Is Important To You, NATCO Pharma (NSE:NATCOPHARM) Presents An Opportunity
Jul 15NATCO Pharma (NSE:NATCOPHARM) Seems To Use Debt Rather Sparingly
Jun 30NATCO Pharma Limited's (NSE:NATCOPHARM) Earnings Are Not Doing Enough For Some Investors
Jun 14NATCO Pharma Limited (NSE:NATCOPHARM) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models
May 30Calculating The Fair Value Of NATCO Pharma Limited (NSE:NATCOPHARM)
May 09Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?
Apr 03NATCO Pharma (NSE:NATCOPHARM) Is Due To Pay A Dividend Of ₹1.25
Feb 21NATCO Pharma Limited Just Beat EPS By 223%: Here's What Analysts Think Will Happen Next
Feb 18NATCO Pharma Limited (NSE:NATCOPHARM) Surges 25% Yet Its Low P/E Is No Reason For Excitement
Feb 17Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?
Jan 25An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 37% Undervalued
Jan 09Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?
Dec 13An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 42% Undervalued
Sep 30Here's Why We Think NATCO Pharma (NSE:NATCOPHARM) Might Deserve Your Attention Today
Sep 12NATCO Pharma (NSE:NATCOPHARM) Is Paying Out A Larger Dividend Than Last Year
Aug 12Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?
Jul 16NATCO Pharma Limited (NSE:NATCOPHARM) Shares Could Be 44% Below Their Intrinsic Value Estimate
Apr 20Is NATCO Pharma Limited (NSE:NATCOPHARM) Trading At A 46% Discount?
Dec 20NATCO Pharma's (NSE:NATCOPHARM) Upcoming Dividend Will Be Larger Than Last Year's
Aug 12Does NATCO Pharma (NSE:NATCOPHARM) Have A Healthy Balance Sheet?
Jun 23Broker Revenue Forecasts For NATCO Pharma Limited (NSE:NATCOPHARM) Are Surging Higher
Jun 02CEO
Rajeev Nannapaneni (47 yo)
12.4yrs
Permanencia
₹98,670,000
Compensación
Sri Rajeev Nannapaneni serves as Chief Executive Officer at NATCO Pharma Limited since April 1, 2022 and also served as Vice Chairman since June 1, 2012 until April 1, 2022 and serves as its Vice Chairman...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| MD & Chairman | 43.2yrs | ₹100.77m | 25.1% ₹ 64.2b | |
| CEO & Vice Chairman | 12.4yrs | ₹98.67m | 0.63% ₹ 1.6b | |
| Chief Financial Officer | 8.8yrs | ₹13.36m | sin datos | |
| President of Technical Affairs & Whole Time Director | no data | ₹33.69m | 0.030% ₹ 77.3m | |
| Company Secretary & Compliance Officer | 2.6yrs | ₹2.61m | sin datos | |
| Executive VP of Corporate Engineering Services & Whole Time Director | no data | ₹20.16m | 0.023% ₹ 58.7m | |
| Executive VP of Technical Operations & Director | 7.8yrs | ₹32.12m | 0.013% ₹ 33.2m | |
| VP & Head of Operations | no data | sin datos | sin datos | |
| Executive Vice President of Corporate Affairs | no data | sin datos | sin datos | |
| Vice President of Marketing & Sales - Domestic | less than a year | sin datos | sin datos | |
| Senior Vice President of HR & Organisational Development | no data | sin datos | 0.0062% ₹ 15.8m | |
| Executive Vice President of R&D | 30.6yrs | sin datos | 0.025% ₹ 62.9m |
7.8yrs
Permanencia media
65yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de NATCOPHARM es experimentado (7.8 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| MD & Chairman | 43.2yrs | ₹100.77m | 25.1% ₹ 64.2b | |
| CEO & Vice Chairman | 19yrs | ₹98.67m | 0.63% ₹ 1.6b | |
| President of Technical Affairs & Whole Time Director | 9.8yrs | ₹33.69m | 0.030% ₹ 77.3m | |
| Executive VP of Corporate Engineering Services & Whole Time Director | 10yrs | ₹20.16m | 0.023% ₹ 58.7m | |
| Executive VP of Technical Operations & Director | 2.3yrs | ₹32.12m | 0.013% ₹ 33.2m | |
| Independent Director | 9.8yrs | ₹330.00k | sin datos | |
| Independent Director | less than a year | sin datos | sin datos | |
| Independent Director | less than a year | sin datos | sin datos | |
| Independent Non-Executive Director | less than a year | sin datos | sin datos | |
| Independent Non-Executive Director | less than a year | sin datos | sin datos | |
| Independent Non-Executive Director | less than a year | sin datos | sin datos |
2.3yrs
Permanencia media
66yo
Promedio de edad
Junta con experiencia: La junta directiva de NATCOPHARM no se considera experimentada (2.3 años de permanencia promedio), lo que sugiere una nueva junta directiva.